CONECTA COVID PROGRAM
DIGITAL BIOCoV: Early prediction of anti-COVID-19 activity on biomolecules present in fungi and microalgae through the application of Machine Learning techniques integrating biological and chemical data.
Companies: Hifas da Terra, AMSbiopharma, CIFGA and Plexus Technologies
Objective: The general objective of this project is to launch an accelerated development through prediction based on the integration of chemical and biological data for the discovery of new anti-COVID-19 treatments from fungal and microalgae extracts.
The consortium that will carry out this project is made up of 3 SMEs and 1 large Galician company: Hifas da Terra (leader of the same), AMSbiopharma, CIFGA, and Plexus, with the support of the University of Santiago de Compostela as a subcontracted collaborating entity , and that they will collaborate jointly for its execution.
Thus, DIGITAL-BIOCoV will make use of the incorporation of digital technologies in research and development during the phase of discovering bioactive fractions or molecules against SARS-CoV-2 from the integration of bioactivity and chemical data that allow their patentability to be explored. , value or originality for the pharmaceutical market.
Total budget: €314,486.93
This project is subsidized by the Galician Innovation Agency (GAIN), financed from ERDF Funds and has the support of the Xunta de Galicia through the second vice-presidency and the Ministry of Economy, Business and Innovation. The operation is financed through the CONECTA COVID 2021 program within the framework of the REACT-EU axis of the Feder Galicia 2014-2020 operational program, as part of the European Union's response to the COVID-19 pandemic.